{
    "pmcid": "11407660",
    "qa_pairs": {
        "What does the study suggest about the evaluation of antibody therapies?": [
            "They should be evaluated across different viral variants to ensure efficacy and safety.",
            "They should focus solely on the receptor-binding domain (RBD).",
            "They should only target the Omicron variant.",
            "They should be evaluated only for their neutralizing capabilities."
        ],
        "What is the unique functionality of the epitope identified on the SARS-CoV-2 spike protein?": [
            "It enhances viral entry for prototypic variants but neutralizes entry for the Omicron variant.",
            "It neutralizes viral entry for all variants.",
            "It enhances viral entry for all variants.",
            "It has no effect on viral entry for any variant."
        ],
        "What structural technique was used to reveal how Nanosota-5 binds to the SARS-CoV-2 spike protein?": [
            "Cryo-EM",
            "X-ray crystallography",
            "NMR spectroscopy",
            "Atomic force microscopy"
        ],
        "Where does Nanosota-5 bind on the SARS-CoV-2 spike protein?": [
            "At the junction of the N-terminal domain (NTD) and subdomain 2 (SD2)",
            "At the receptor-binding domain (RBD)",
            "At the S2 subunit",
            "At the fusion peptide region"
        ],
        "Which nanobody was found to be most effective in enhancing viral entry for prototypic SARS-CoV-2 variants?": [
            "Nanosota-5",
            "Nanosota-6",
            "Nanosota-7",
            "Nanosota-8"
        ]
    }
}